LG화학, 차세대 소아마비백신 본격 공급
소아마비백신 ‘유폴리오(Eupolio)’를 공급하는 계약
*아래는 위 기사를 구글 번역기로 번역한 영문 기사의 [전문]이다. [Below is the [full text] of an English article translated from the above article with Google Translate.
LG Chem to supply next-generation polio vaccine in earnest
Contract to supply polio vaccine “Eupolio”
[The story of the case / Reporter Park Yeon-pa] = LG Chem is in full swing to supply the next-generation polio vaccine to solve the global public health problem for children.
On the 7th, LG Chem is supplying the polio vaccine'Eupolio' with UNICEF, an international relief organization, for a total of 80 million dollars (approximately 87 billion won) between 2021 and 2022 to solve the recurrent polio disease worldwide. He said he had signed a contract.
'Ufolio' is a next-generation dead vaccine that has undergone an additional process of chemically removing the pathogenicity of the virus using an attenuated virus (a virus with weakened toxicity). ), it has a greater advantage in terms of safety.
Most of the recent outbreaks of polio are estimated to be due to the virus remaining in the manure of children taking live vaccines mixed with drinking water and spreading to local communities.
At the end of December 2020, LG Chem received the world's first'Sabin IPV' approval from the WHO,'PQ (Pre-Qualification)', which is a mandatory screening for the supply of a vaccine to the International Aid Organization. Based on its excellence, it signed a large-scale supply contract in just three weeks, and will start supplying it to more than 70 countries around the world, centering on the Middle East, Africa, and Southeast Asia, starting next month.
With this contract, LG Chem will supply more than 20% of UNICEF's total procurement, and will quickly become UNICEF's top 3 polio vaccine supplier.
LG Chem plans to actively contribute to solving the global children's public health problem by doubling its production capacity by 2022 to resolve the supply shortage of polio vaccines.
Shortening the development period through active investment to resolve supply shortcomings, also facing the Bill Gates Foundation
In the process of expanding the transition from live vaccine to dead vaccine, LG Chem is expected to gradually worsen the supply and demand of dead vaccine, and at the end of 2014, it began to develop a safe and effective vaccine.
In fact, in 2014, the WHO declared the “State of Emergency” for the first time in order to prevent a re-outbreak of the virus due to the shortage of polio vaccine supply.
From the beginning of development, LG Chem has made rapid progress in clinical product production and process development with active facility investments. A total of $576,000 (approximately 63 billion won) has been provided for the portfolio-based 6-valent vaccine project.
Based on the support of the Bill & Melinda Gates Foundation and effective clinical and licensing strategies, LG Chem shortened the development period from nearly 10 years to 6 years and successfully commercialized the product.
Ji-woong Sohn, head of the Life Sciences Business Division, said, “Through the establishment of a global cooperation model with the Bill & Melinda Gates Foundation and UNICEF, LG Chem has played an important role as a major global supplier of polio vaccines. And I will actively develop an effective vaccine.”
Meanwhile, LG Chem has provided three vaccines, including the supply of'Ufolio' (Hepatitis B vaccine'Ubox' in 1996, and'Upenta', a pentavalent combination vaccine in 2016) all over the world through international aid organizations. And is currently developing phase 2 clinical trials of a hexavalent mixed vaccine based on'Ufolio'.
<저작권자 ⓒ 사건의내막 무단전재 및 재배포 금지>